Ultrasound-guided Tru-Cut Biopsy in Pelvic Masses

What this Trial Is About

Ovarian cancer is a leading cause of death among gynecological cancers, often diagnosed late and sometimes involving metastases from other primary tumors. This research aims to evaluate the safety and tissue yield of ultrasound-guided transvaginal or transrectal tru-cut biopsy in patients with pelvic tumors. The study also looks at factors influencing biopsy reliability, patient experience, pain, and compares biopsy results to final surgical histology when available. Participants undergo a minimally invasive tru-cut biopsy using an 18G needle guided by ultrasound to collect tissue samples from pelvic masses. The biopsies are performed by experienced gynecologic ultrasound operators, and tissue is analyzed by specialized pathologists. The study is observational and collects data on safety, tissue adequacy, patient pain and experience, and correlates biopsy findings with surgery outcomes if applicable. During the study, patients' pain and overall experience are assessed within 72 hours post-biopsy using a numeric rating scale. Safety and complication rates are monitored up to six weeks after the procedure through data review and follow-up assessments including phone calls. The main outcomes measured at six weeks are safety (absence of complications) and tissue yield (sufficient tissue for analysis). Secondary outcomes include factors affecting these results, patient discomfort, and histological diagnosis accuracy.

Ultrasound-guided Tru-Cut Biopsy in Pelvic Masses.